Cover Image
市場調查報告書

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症) :開發中產品分析

Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 361618
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症) :開發中產品分析 Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 63 Pages
簡介

本報告提供次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症) 的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症)的概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):企業開發中的治療藥

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):大學/機關研究中的治療藥

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):企業開發中的產品

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):大學/機關研究中的產品

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症)的治療藥開發企業

  • Forendo Pharma Limited
  • Merck & Co., Inc.
  • Mereo Biopharma Group Limited
  • Millennium Pharmaceuticals, Inc.
  • Repros Therapeutics Inc.

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):最近的開發平台趨勢

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):暫停中的計劃

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):開發中止的產品

次發性性腺功能低下症 (促性腺激素不足之性腺功能低下症):產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8114IDB

Summary

Global Markets Direct's, 'Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 2016', provides an overview of the Secondary (Hypogonadotropic) Hypogonadism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary (Hypogonadotropic) Hypogonadism and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Secondary (Hypogonadotropic) Hypogonadism
  • The report reviews pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Secondary (Hypogonadotropic) Hypogonadism therapeutics and enlists all their major and minor projects
  • The report assesses Secondary (Hypogonadotropic) Hypogonadism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Secondary (Hypogonadotropic) Hypogonadism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Secondary (Hypogonadotropic) Hypogonadism Overview
  • Therapeutics Development
    • Pipeline Products for Secondary (Hypogonadotropic) Hypogonadism - Overview
    • Pipeline Products for Secondary (Hypogonadotropic) Hypogonadism - Comparative Analysis
  • Secondary (Hypogonadotropic) Hypogonadism - Therapeutics under Development by Companies
  • Secondary (Hypogonadotropic) Hypogonadism - Therapeutics under Investigation by Universities/Institutes
  • Secondary (Hypogonadotropic) Hypogonadism - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Secondary (Hypogonadotropic) Hypogonadism - Products under Development by Companies
  • Secondary (Hypogonadotropic) Hypogonadism - Products under Investigation by Universities/Institutes
  • Secondary (Hypogonadotropic) Hypogonadism - Companies Involved in Therapeutics Development
    • Forendo Pharma Limited
    • Merck & Co., Inc.
    • Mereo Biopharma Group Limited
    • Millennium Pharmaceuticals, Inc.
    • Repros Therapeutics Inc.
  • Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BGS-649 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • corifollitropin alfa - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • enclomiphene citrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fispemifene - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Kisspeptin-10 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MSS-722 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAK-448 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • testosterone undecanoate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Secondary (Hypogonadotropic) Hypogonadism - Recent Pipeline Updates
  • Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects
  • Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products
  • Secondary (Hypogonadotropic) Hypogonadism - Product Development Milestones
    • Featured News & Press Releases
      • Mar 28, 2016: Apricus Reports Top-Line Phase 2b Data for Fispemifene in Symptomatic Secondary Hypogonadism
      • Mar 15, 2016: Repros Announces Initiation of Formal Approval Process by the European Medicines Agency
      • Feb 16, 2016: Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men
      • Feb 08, 2016: Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism
      • Feb 02, 2016: Apricus Biosciences to Present at the 18th Annual BIO CEO & Investor Conference and Provide Update on Fispemifene
      • Jan 11, 2016: Repros Announces Court of Appeals' Affirmation of Summary Judgment in Favor of the Company
      • Jan 04, 2016: Repros Updates Enclomiphene Program
      • Dec 01, 2015: Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene
      • Dec 01, 2015: Apricus Biosciences Confirms Clinical Strategy for Its Novel Treatment for Symptomatic Secondary Hypogonadism Fispemifene
      • Oct 29, 2015: Repros Therapeutics Announces Cancellation of FDA Advisory Committee Meeting to Review Enclomiphene for the Treatment of Secondary Hypogonadism
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H1 2016
  • Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Forendo Pharma Limited, H1 2016
  • Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Merck & Co., Inc., H1 2016
  • Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Mereo Biopharma Group Limited, H1 2016
  • Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Repros Therapeutics Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Secondary (Hypogonadotropic) Hypogonadism Therapeutics - Recent Pipeline Updates, H1 2016
  • Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects, H1 2016
  • Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H1 2016
  • Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top